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OBJECTIVES We determined the electrocardiographic, vascular and clinical effects of a medical food bar
enriched with L-arginine and a combination of other nutrients known to enhance
endothelium-derived nitric oxide (NO) in patients with stable angina.
BACKGROUND Enhancement of vascular NO by supplementation with L-arginine and other nutrients has
been shown to have clinical benefits in patients with angina secondary to atherosclerotic
coronary artery disease (CAD). However, the amounts and combinations of these nutrients
required to achieve a clinical effect make traditional delivery by capsules and pills less suitable
than alternative delivery methods such as a specially formulated nutrition bar.
METHODS Thirty-six stable outpatients with CAD and class II or III angina participated in a
randomized, double-blind, placebo-controlled, crossover trial with two treatment periods
each of two weeks’ duration (two active bars or two placebo bars per day). Flow-mediated
brachial artery dilation was measured by ultrasound. Electrocardiographic measures of
ischemia, exercise capacity and angina onset time were measured by treadmill exercise testing
and by Holter monitor during routine daily activities. Quality of life was assessed by SF-36
and Seattle Angina Questionnaires and by diary.
RESULTS The medical food improved flow-mediated vasodilation (from 5.5  4.5 to 8.0  4.9, p 
0.004), treadmill exercise time (by 20% over placebo, p  0.05) and quality-of-life scores
(SF-36 summary score; 68  13 vs. 63  21 after placebo, p  0.04, Seattle Angina
Questionnaire summary score; 67  10 vs. 62  18, p  0.04) without affecting electrocardio-
graphic manifestations of ischemia or angina onset time.
CONCLUSIONS These findings reveal that this arginine-rich medical food, when used as an adjunct to
traditional therapy, improves vascular function, exercise capacity and aspects of quality of life
in patients with stable angina. (J Am Coll Cardiol 2002;39:37–45) © 2002 by the
American College of Cardiology
Atherosclerotic coronary artery disease (CAD) is responsi-
ble for angina and is the leading cause of mortality in the
developed world. Many risk factors for CAD are associated
with a reduced elaboration of nitric oxide (NO) by the
endothelium (1–3). A new therapeutic strategy for individ-
uals with CAD is to restore NO activity, thereby facilitating
vasodilation and increasing resistance to thrombosis and
atherosclerosis. For example, the restoration of vascular NO
activity by HMG CoA reductase inhibitors is associated
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with improvements in vasodilation and a reduction in
cardiovascular mortality beyond that which would be ex-
pected from their effects on lipid levels and vascular struc-
ture (4,5). A number of naturally occurring products may
also enhance vascular NO activity. Among these is
L-arginine, the precursor to NO, as well as folic acid,
vitamins B6 and B12, vitamin C, vitamin E, phytoestrogens
and niacin (6–15).
Accordingly, a medical food was developed that contains
L-arginine and these additional nutrients. In previous stud-
ies this medical food was demonstrated to improve flow-
mediated vasodilation in middle-aged individuals with hy-
percholesterolemia and to increase walking distance and
enhance quality of life in patients with claudication second-
ary to peripheral arterial disease (16,17). This study was
designed to study the vascular, electrocardiographic and
clinical effects of this medical food in patients with stable
angina.
METHODS
Study design. The study was a randomized, double-blind,
placebo-controlled crossover trial of dietary supplementa-
tion for two-week treatment periods with two active bars/
day (active period) and two placebo bars/day (placebo
period). The short course of therapy was chosen so that the
acute vascular effects of the bar could be assessed in isolation
from any beneficial effects that it may have on vascular
structure, inflammation and thrombosis.
The first treatment period was preceded by the collection
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of baseline data (baseline period), and the two treatment
periods were separated by a month-long washout (washout
period). The primary objective of the study was to examine
the effect of the treatments on the time to onset of
ST-segment depression compared with before treatments.
Secondary outcomes include other treadmill exercise param-
eters, ambulatory electrocardiogram (ECG) (Holter) mea-
sures, quality-of-life measures, Medical Outcomes Study
Health Survey (SF-36) and Seattle Angina Questionnaire
scores and measures of flow-mediated endothelial function.
All subjects signed an informed consent before undergo-
ing screening procedures. At the screening visit, a medical
history was collected, and a physical exam and treadmill
testing were performed. Qualifying subjects returned for
baseline treadmill testing, a brachial artery ultrasound study,
quality-of-life measures and 48-h Holter monitoring during
routine daily activities. Venous blood samples were taken for
determination of serum lipid, chemistry and hematologic
values. Subjects were randomized to begin one or the other
treatment periods after removal of the Holter monitor.
Subjects were instructed to take the study bars with or
between meals separated by at least 4 h. Subjects were also
instructed in the use of the study diary. At the end of both
two-week treatment periods and the four-week washout
period, subjects returned for repeat studies after an over-
night fast and 1 to 2 h after consuming the last study bar.
Subjects were also instructed to continue their current
medications but withhold any doses of beta-adrenergic
blocking agents and nitrate-containing drugs scheduled
within 4 h of treadmill testing until after the procedure. The
procedures followed in this study were in accordance with
the ethical standards of the approving independent review
board and with the Helsinki Declaration of 1975, as revised
in 1983.
Subjects. Eligible subjects were adults with chronic, stable
angina (Canadian Cardiovascular Society class II and III)
with ST-segment depression of 1 mm or more before
achieving 14.5 metabolic equivalents of the task (METS)
during treadmill exercise testing. The presence of CAD was
verified by documented evidence of a myocardial infarction,
an abnormal stress test or coronary angiogram demonstrat-
ing 50% luminal obstruction of 1 epicardial coronary
artery or major branch. Subjects were excluded if they had
unstable angina (rest angina or a change in clinical condition
within the previous two months), a myocardial infarction,
major surgery or angioplasty within the previous three
months, symptomatic heart failure, impaired renal or he-
patic function or any other systemic illness. Subjects were
also excluded for presence of congenital heart disease,
valvular heart disease, atrial fibrillation, uncontrolled hyper-
tension, type I diabetes, any disease process other than
CAD that would cause early termination of treadmill
testing and hypersensitivity to any components in the bar.
Subjects were required to discontinue L-arginine and
L-lysine-containing products 28 days before acquiring base-
line data. Subjects were otherwise asked to continue their
regular medications, diet and lifestyle habits and were free to
follow any other medical care regimens.
Study product. The active bar is an L-arginine-enriched
nutrient bar (HeartBar, Cooke Pharma, Silver Springs,
Maryland). Each 50-g active bar contains 3.3 g of
L-arginine as well as antioxidant vitamins and minerals,
folic acid and B vitamins in a soy protein and oat fiber base.
Each placebo bar is similar to the active bar with respect to
weight, appearance and flavor as well as caloric, carbohy-
drate, protein, fiber and fat content but is not supplemented
with L-arginine and is devoid of added vitamins and
minerals. In addition, the protein source of the placebo bar
is mixed milk protein and whey (which are L-arginine-
poor) rather than soy (L-arginine-rich). The components of
the active and placebo bars are listed in Table 1. All bars
were individually wrapped in plain white wrappers. Both
wrappers and cases containing the bars were coded in order
to keep subjects and study personnel blinded. Previous
studies demonstrated that subjects are unable to distinguish
between active and placebo bars by appearance, taste,
texture or outer markings.
Abbreviations and Acronyms
ACIP  Asymptomatic Cardiac Ischemia Pilot study
CAD  coronary artery disease
MET  metabolic equivalent of the task
NO  nitric oxide
SF-36  Medical Outcomes Study Health Survey
Table 1. Nutrition Content of Active and Placebo Bars
Active Placebo
Size 50 g 50 g
Calories 180 170
Ingredient Amount (%DV) Amount (%DV)
Total fat 3 g 1.5 g
Saturated 0 g 0 g
Polyunsaturated 1.5 g 0 g
Monounsaturated 0.5 g 1 g
Cholesterol 0 mg 10 mg
Total carbohydrate 25 g 30 g
Dietary fiber 3 g 2 g
Sugars 15 g 13 g
Sugar alcohol 5 g 10 g
Protein 14 g 13 g
L-arginine 3.2  0.2 g 0.59  0.04 g
L-cystine 0.10 g 0.14 g
Vitamin C 250 mg 420% 0 mg 0%
Vitamin E 200 IU 670% 1 IU 2%
Niacin 25 mg 130% 0 mg 0%
Vitamin B6 2 mg 100% 0 mg 0%
Vitamin B12 4.8 g 80% 0.4 g 6%
Folate 200 g 50% 16 g 4%
Soy isoflavones 40 mg 0 mg
Composition of active and placebo bars. Percent daily values (%DV) are based on a
2,000 calorie diet. L-cysteine content also included because L-cysteine can be
converted into glutathione, which may have an effect on vascular function. The
L-cysteine content between the two treatments is not substantially different.
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Exercise treadmill testing. Treadmill testing (Burdick
TAG20 Controller, Spacelabs Medical, Redmond, Wash-
ington) was performed using the Asymptomatic Cardiac
Ischemia Pilot study (ACIP) variable-grade and speed
treadmill protocol (18). A Modified ACIP protocol was
used for those with difficulty walking at 3 mph. Subjects
continued to walk until they experienced excessive fatigue or
angina, 2-mm ST-segment depression or other typical
indications for stopping exercise (19). Time to onset of
ST-segment depression was determined by identifying the
earliest time that any lead, other than aVR, demonstrated
1 mm of horizontal or downsloping ST-segment depres-
sion. Treadmill data were analyzed without knowledge of
treatment assignment by Brigham & Women’s Hospital
Exercise Testing Core Laboratory.
Ambulatory ECG monitoring. Three-channel Holter
monitors (Brentwood, Torrance, California) with digital
recording were placed at the end of each visit and removed
48 h later. Patients were encouraged to continue their
routine daily activities while wearing the monitor. Holter
data were analyzed for the cumulative time any channel
demonstrated 1-mm ST-segment depression and for the
cumulative number of ischemic events. Holter studies were
analyzed without knowledge of treatment assignment by
Brigham & Women’s Hospital Holter Core Laboratory.
Vascular function. Vascular function was measured while
subjects were fasting by assessing brachial artery flow-
mediated (endothelium-dependent) vasodilation using
high-resolution ultrasound (15 MHz vascular probe, Acu-
son Sequoia, Mountain View, California). The method is
described previously in detail (16) except Brachial Tools
DICOM 3.2.1 software (Medical Imaging Applications,
Iowa City, Iowa) was used to analyze ultrasound images.
Fourteen age- and gender-matched healthy controls with no
cardiovascular risk factors by history or laboratory examina-
tion were recruited as controls for this particular portion of
the study.
Quality of life. Quality of life was measured by means of
the Medical Outcomes Study Health Survey (SF-36), by the
Seattle Angina Questionnaire (Medical Outcomes Trust,
Boston, Massachusetts) and by study diary analysis (20–22).
The Seattle Angina Questionnaire has been validated and
found to relate to Canadian Cardiovascular Society classi-
fication and to be sensitive to changes in disease over time
(23). Using the study diary, subjects were asked to record
any chest pain episodes and the use of nitroglycerin.
Safety and adverse events. Safety was monitored by survey
for adverse events and by analyses of serum lipid, chemistry
and hematology, which were performed by Unilab (San
Jose, California).
Statistical analysis. Data are presented in Tables as mean
SD and in the graph as mean  SEM before and after each
treatment period. Hypothesis testing was performed em-
ploying mixed model repeated measures (SAS PROC
MIXED, V8: SAS Institute, Cary, North Carolina). Sub-
jects were treated as random effects and treatment as a fixed
effect. A first-order autoregressive covariance structure was
used to allow for declining correlations within individuals
over time. As a supplemental analysis, Wilcoxon rank-sum
tests were used to analyze changes in times to onset of
1-mm ST-segment depression and angina. It was hypoth-
esized that the active treatment would improve maximum
vasodilation, total exercise time and work performed; there-
fore, these were one-tailed tests. All other tests were
two-tailed. Frequencies of events were compared with
McNemar’s chi-square test (24). An alpha level of 0.05 was
used to establish statistical significance for all tests.
RESULTS
Demographics. Of 86 individuals screened, 36 met the
inclusion/exclusion criteria and were randomized. The rea-
sons for screening failure included failure to attain 1-mm
ST-segment depression before treadmill termination (n 
23), abnormal rhythm interfering with interpretation (n 
9), insufficient independent documentation of CAD (n 7)
and miscellaneous (n  11). The characteristics of the
subjects in each group are given in Table 2. There were no
dropouts during the 10-week study. All patients remained
above 75% compliance during both periods (97  1% and
99  2% for the active and placebo periods, respectively)
except for one patient who maintained 57% compliance
during the placebo period. There were no statistical differ-
ences in any measures of outcomes between initial baseline
and washout periods, demonstrating that the month-long
washout period was sufficient to return to baseline values.
Exercise treadmill testing. All subjects developed 1-mm
ST-segment depression at screening. Thirty-one subjects
developed 1-mm ST-segment depression during the active
period while 28 developed 1-mm ST-segment depression
during the placebo period. There was no treatment effect on
the time to onset of 1-mm ST-segment depression by either
mixed model or rank-sum testing (Table 3).
While there was no effect on the time to onset of
ST-segment depression, total exercise time increased by
16% on average in the active period compared with a 4%
decrease in treadmill time during the placebo period (p 
0.05). A tendency toward increased total work performed
(METS-min) was observed in the active period (27% on
average), compared with a decrease (6% on average)
during the placebo period (p  0.06). Despite the increase
in exercise time during the active period, there was no effect
on the peak magnitude of ST-segment depression summed
across all leads or on peak rate-pressure product during the
active period.
Thirty-one subjects experienced angina during treadmill
testing on at least one of the four phases. The percentage of
patients who experienced angina during treadmill testing
was similar during the active and placebo treatments (75%
vs. 64%, p  NS) (Table 3). There was no treatment effect
on the time to onset of angina.
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Ambulatory ECG monitoring. Analysis of cumulative
ischemia during ambulatory activity was confined to the
subjects who successfully completed all four periods with
36 h of acceptable Holter recordings (n  15). There was
no significant effect of either treatment on cumulative
ischemic time (23  45 to 17  37 min per 48-h period
before and after the active treatment vs. 18 37 to 14 31
before and after placebo) or number of ischemic events after
either treatment period. Hour-by-hour analysis of ECG
recordings revealed no relation of the depth and extent of
ischemia with the timing of bar consumption.
Vascular function. Maximum vasodilation before both the
active and placebo periods was reduced compared with
healthy controls (n  14, 8.6  4.9%, p  0.02 vs.
before-active period, p  0.05 vs. before-placebo period)
(Fig. 1). However, maximum vasodilation improved signif-
icantly during the active period compared with the before-
active period (8.0  4.9 vs. 5.5  4.5, respectively, p 
0.004). No change was seen during the placebo period
compared with the before-placebo period (5.8  5.3 vs.
5.8  6.4, respectively, p  0.95).
Quality of life. Subjects reported an improvement in
quality of life as demonstrated by an improvement from
baseline to the end of the active period in the summary
SF-36 score (baseline  64  14 to active  68  13, p 
0.04). The SF-36 scores after the active period were also
significantly better than those after the placebo period (63
21, p  0.04). Results by domain are detailed in Table 4.
The improvement in the summary SF-36 can be attributed
to the physical component with an improvement from
baseline to the active period in the aggregate score from
41  9 to 44  9 (p  0.03). The difference between the
active and placebo periods (41  11) was marginal (p 
0.08) due to increased variability after the placebo period.
No significant changes were seen for the aggregate mental
score between any periods. Among the individual compo-
nents, vitality and role-physical scores improved most sig-
nificantly from baseline to the active period; however, only
vitality and bodily pain scores during the active period were
significantly better than those during the placebo period.
The SF-36 aggregate physical component scores were con-
verted to Z-scores (numbers of SD from a reference mean)
to compare with the age- and gender-matched healthy
population (Table 4). The mean aggregate physical score
was 0.87 SD below the healthy population at baseline. This
score improved to 0.60 SD below the mean of the healthy
population during the active period while there was no
improvement during the placebo period.
Summary Seattle Angina Questionnaire scores corrobo-
rated SF-36 results by showing improvement from baseline
and in comparison with placebo scores (p  0.0004 and
0.04, respectively). Four of five components of the Seattle
Angina Questionnaire significantly improved after the ac-
tive period, although only treatment satisfaction was signif-
icantly better than that after the placebo period (Table 4).
Diary analysis demonstrated no change in chest pain
frequency during any portion of the study (Table 4). There
was, however, a decrease in nitroglycerin use during both
treatment periods (p  0.003 and 0.002 for active and
placebo periods, respectively).
Evaluation of safety. There were no differences between
the placebo and active periods in parameters of safety. There
were no significant changes in values with respect to serum
chemistry, hematologic or lipid levels except for a significant
Table 2. Baseline Data of Subjects
Demographics Mean  SD
n 36
Age (yrs) 65.9  10
Weight (lbs) 189  36
Men/women (#) 28/8
Caucasian (#) 32
African American (#) 2
Medical History #, (% of Total)
CCS angina class II/III 21/15
w/Hx of myocardial infarction 8 (22%)
w/Hx of CABG 8 (22%)
w/Hx coronary angioplasty 5 (14%)
w/Hypertension 17 (47%)
w/Diabetes 5 (14%)
w/Hypercholesterolemia 19 (52%)
w/Claudication 6 (17%)
w/Erectile dysfunction (% of men) 5 (18%)
Systolic BP (mm Hg) 134  16
Diastolic BP (mm Hg) 76  11
Total cholesterol (mg/dl) 195  57
Habits #, (% of Total)
On self-reported low-fat diet 16 (44%)
On exercise program 22 (61%)
Ever smokers 21 (58%)
Alcoholic drinks/day 0.8  1.0
Concomitant Medications #, (% of Total)
Aspirin 28 (78%)
Beta-blocker 19 (53%)
Reg. nitrates (patch or oral) 14 (39%)
Lipid-lowering Rx 22 (61%)
Calcium antagonist 15 (42%)
ACE inhibitor 4 (11%)
Antiocoagulation 0 (0%)
Hypoglycemic 7 (19%)
Estrogen replacement 6 (17%)
Concomitant Nutraceuticals #, (% of Total)
Multivitamin 15 (42%)
Vitamin E (200 IU) 3 (8%)
Vitamin C (250 mg) 1 (3%)
Niacin 5 (14%)
Folic acid 3 (8%)
Coenzyme Q10 6 (17%)
Other antioxidants 17 (47%)
Baseline demographic and medical data of subjects. Alcoholic drinks of differing types
were converted to one standard.
ACE angiotensin-converting enzyme; BP blood pressure; CABG coronary
artery bypass graft; CCS  Canadian Cardiovascular Society.
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reduction in uric acid over the two-week active period (5.4 
1.0 to 4.7  1.0 mol/l, p  0.005 and vs. placebo of 5.3 
1.0, p  0.0003). No serious adverse events were reported
during the study. Eleven of 36 subjects reported minor
adverse events during the active period, while 10 reported
events during the placebo period. Minor adverse events
included: flatulence (two active and two placebo), bowel
habit change (one active, two placebo), increased chest pain
Table 3. Treadmill Data of Subjects Before and After Two Weeks of Therapy
Active Period Placebo Period p Value
Variables at onset of 1-mm ST segment depression
Frequency of occurrence (#) (%)
Before 29 (81%) 30 (89%)
After 31 (86%) 28 (81%) 0.3
Time of onset (s, n  28†)
Before 435  212 452  217
After 421  217 403  181** 0.2
Rate-pressure product (beats/min  mm Hg  102,
n  28†)
Before 164  38 160  33
After 167  38 165  44 0.9
Variables at exercise termination (n  36)
Time to termination (s)
Before 574  394 567  251
After 664  763** 545  239 0.05
Freq. of increase in exercise time 25% (#) (%) 6 (17%) 2 (6%) 0.1
Maximal magnitude of ST segment depression in
any lead (mm)
Before 1.5  0.8 1.3  0.9
After 1.6  0.9 1.4  0.9 0.3
Magnitude of ST segment depression across
12 leads (mm)
Before 6.2  4.4 5.3  3.7
After 5.8  3.9 5.6  4.5 0.3
Rate-pressure product (beats/min  mm Hg  102)
Before 197  43 187  49
After 194  49 199  53 0.8
Total work performed (METS-min)
Before 69  76 65  40
After 87  161** 61  39 0.06
Maximum heart rate (% predicted for age)
Before 81  12 79  18
After 83  15 83  15* 0.5
Frequency of reasons for exercise termination
Onset of 2-min ST segment depression (#)
Before 14 6
After 8 10 0.5
Angina severe enough to consider TNG (#)
Before 9 12
After 13 12 0.5
Fatigue (#)
Before 11 15
After 13 10 0.5
Other (#)
Before 2 2
After 2 3 0.5
Variables at onset of angina
Frequency of angina onset (#)
Before 25 (69%) 24 (67%)
After 27 (75%) 23 (64%) 0.3
Time of onset (s, n  19†)
Before 312  114 311  143
After 315  139 319  116 0.9
Treadmill data of subjects before and after two weeks of active and placebo treatment.
*p  0.05; **p  0.01 vs. before intervention. †Values reported are for subpopulation that attained 1-mm ST segment
depression or angina on all four occasions; p value: active vs. placebo by mixed model repeated measures analysis for all data
except frequency data which was analyzed by chi-square.
MET  metabolic equivalent of the task; TNG  trinitroglycerin.
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or leg pain (two active), headache (one active, one placebo),
outbreak of cold sores (one active), bloating (one active),
increase in blood glucose (one active), hematochezia (one
placebo), colitis (one placebo), increased fatigue (one pla-
cebo) and rash (one placebo).
DISCUSSION
This study indicates that this L-arginine-enriched medical
food may be a useful nutritional adjunct to traditional
medical therapy in patients with CAD. Specifically, our
findings demonstrate that therapy with two active bars/day
for two weeks significantly improved brachial artery NO-
mediated vascular function and improved treadmill exercise
capacity by 20% compared with placebo. Due to the design
of the ACIP protocol, this increase in exercise time results
in a 33% increase in work performance. Despite the im-
provement in treadmill exercise capacity with therapy, there
was no increase in electrocardiographic manifestations of
ischemia or cardiac work as measured by rate-pressure
product. These objective findings were associated with
significant improvements in several parameters measuring
quality of life.
Study rationale. The rationale for this current investiga-
tion is provided by a series of studies over the past decade
documenting that the administration of L-arginine can
improve endothelium-dependent vasodilation, coronary
blood flow and symptoms in patients with CAD. During
coronary artery catheterization, a single intravenous infusion
of L-arginine and long-term administration of oral
L-arginine (9 g/day for six months) improve coronary blood
flow response to acetylcholine in these patients (25–31).
Similarly, an endothelial vasodilator dysfunction of the
brachial artery exists in young men with documented CAD,
which is reversed by L-arginine administration (32). These
beneficial effects of L-arginine on vasodilator function have
clinical consequences. Concomitant with the reversal of
endothelial vasodilator dysfunction in patients with CAD,
L-arginine supplementation modestly lowers mean arterial
pressure, reduces total peripheral resistance, increases car-
diac output, increases exercise capacity and improves angina
symptom scores (31,33,34). L-arginine supplementation
may also have beneficial effects on plaque formation; it
appears to slow the progression and may even cause regres-
sion of atherosclerotic plaque in animals (35).
Comparison with previous studies. In the current study,
the 20% increase in treadmill exercise time in this popula-
tion was similar to that which we reported for this therapy
in patients with peripheral arterial disease (17). In that
study, patients with claudication were able to increase their
total walking time by 23% after two weeks of therapy. They
also demonstrated an improvement in pain-free walking
distance (by 66%). These findings are also comparable with
three other studies examining the effects of supplemental
L-arginine on exercise capacity in patients with stable
angina. In one, three days of oral supplementation with 6 g
of L-arginine resulted in a 30% increase in work perfor-
mance (34). These investigators followed their study with a
second crossover study of three days duration (6). In that
study, there was a 7% increase in exercise duration and no
change in the sum of ST-segment depression at peak
exercise. Contrary to our findings, however, there was a 9%
increase in the time to onset of 1-mm ST-segment depres-
sion. They also found no change in the amount of QT
dispersion, an exercise-induced occurrence that is associated
Figure 1. Percent increase in brachial artery diameter in response to increased flow before and after two weeks of active and placebo treatment. Age- and
gender-matched controls are also provided (n  14). Values in mean  SEM, §p  0.05 versus controls; **p  0.01 vs. before treatment; †p  0.05 vs.
placebo.
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with greater risk of sudden cardiac death. In a third study,
a one-time infusion of L-arginine resulted in no improve-
ment in measures of exercise capacity but did decrease the
time to recovery from myocardial ischemia (8).
The increase in exercise time observed here compares
favorably with recent studies of anti-anginal drug therapies.
In a study comparing propranolol, diltiazem and nifedipine
in patients with stable angina, only diltiazem improved
exercise duration (by 8%) (36). Another group reported a
12% increase over placebo in exercise duration for diltiazem
after 12 weeks in a study comparing calcium channel
blockers (37). The Monotherapy Assessment of Ranolazine
in Stable Angina (MARISA) investigators recently reported
a 10% increase over placebo in symptom-limited exercise
duration after one week during peak ranolazine levels (38).
In that study, subjects were withdrawn from other anti-
anginal medications in order to increase the likelihood of
observing an effect of therapy. By contrast, in the current
study, patients continued on their existing anti-anginal
medications throughout the investigation.
In contrast with the effects observed for exercise capacity,
we did not observe any effects on angina onset time or ECG
manifestations of ischemia during treadmill testing nor on
cumulative ischemic time during routine ambulatory activ-
ities. The lack of beneficial effect on angina and ischemia
onset times during treadmill testing may be partly explained
by the fact that our study patients were receiving multiple
anti-anginal therapies such as beta-blockers, organic nitrates
and calcium channel blockers. Most studies designed to
determine the effects of new anti-anginal therapies on
ST-segment depression require the withdrawal of standard
anti-anginal medications (particularly beta-blockers) before
enrollment in order to assess efficacy of the study drug.
However, because the medical food is a nutritional adjunct
to standard medications, these medications were not with-
drawn.
Evidence for mechanism of action. The lack of effect on
ECG manifestations of ischemia during maximal exercise
should be placed in the context of the amount of work
performed. Despite the same degree of ischemia at maximal
exercise with active treatment as with placebo, subjects were
able to exercise 20% more during the active period. The
increased exercise time without an increase in degree of
ischemia likely reflects a decrease in myocardial oxygen
demand (i.e., decreased heart rate and blood pressure)
during submaximal exercise, an anti-ischemia mechanism
Table 4. Quality of Life Data of Subjects Before and After Two Weeks of Therapy
Baseline Active Period Placebo Period p Value
SF-36 Data (n  36)
Scores for individual components
(Z-scores in italics):
Physical functioning 66  20 (0.80  0.9) 67  17 (0.76  0.7) 64  27 (0.88  1) 0.7
Role-physical 56  35 (0.73  1) 72  36† (0.28  0.1) 65  43 (0.47  1) 0.1
Bodily pain 60  29 (0.65  1) 64  27 (0.47  1) 52  25* (1.0  1) 0.001
General health 57  18 (0.74  0.9) 61  17 (0.57  0.8) 56  22 (0.79  1) 0.1
Vitality 54  20 (0.34  0.9) 60  17* (0.05  0.8) 54  24 (0.36  0.1) 0.03
Social functioning 90  14 (0.31  0.6) 90  16 (0.30  0.7) 88  24 (0.20  1) 0.2
Role-emotional 45  12 (1.1  0.4) 47  9 (1.05  0.2) 43  16 (1.1  0.5) 0.1
Mental health 82  14 (0.37  0.8) 82  15 (0.42  0.8) 78  21 (0.20  1) 0.1
Aggregate scores:
Aggregate physical component
(norms for healthy  44.6  11)
41  9 (0.87  0.9) 44  9* (0.61  0.9) 41  11 (0.89  1) 0.08
Aggregate mental component
(norms for healthy  51.7  11)
51  7 (0.06  0.7) 51  7 (0.08  0.7) 49  9 (0.06  0.8) 0.3
Summary score 64  14 68  13* 63  21 0.04
Seattle Angina Questionnaire (n  36)
Scores for individual components:
Exertional capacity 60  14 64  15* 60  21 0.1
Anginal stability 54  16 67  22† 60  22 0.1
Anginal frequency 64  21 67  19 66  24 0.4
Treatment satisfaction 70  19 77  15† 70  23 0.02
Disease perception 53  20 61  16† 56  23 0.07
Summary score 60  12 67  10‡ 62  18 0.04
Study Diary (n  31)
Washout Period Active Period Placebo Period p Value
Anginal frequency (# chest pain episodes/week) 4.4  7.5 4.6  7.4 4.0  6.2 0.3
# nitroglycerin tabs taken/week 2.4  3.3 1.3  1.4 1.6  1.6 0.3
Quality-of-life data of subjects before and after two weeks of active and placebo treatment. SF-36 data are presented both as absolute scores and as Z-scores (SD from mean
of healthy age-matched controls), which are given in italics next to the absolute scores.
p value: active vs. placebo, *p  0.05; †p  0.01; ‡p  0.005 vs. before intervention.
43JACC Vol. 39, No. 1, 2002 Maxwell et al.
January 2, 2002:37–45 A Medical Food for Angina
shared by most anti-anginal medications. The fact that the
rate-pressure product at maximal exercise was the same in
all periods supports this hypothesis. These findings would
be consistent with an improvement in peripheral blood flow
during maximal exercise, which would be an expected conse-
quence of improved flow-mediated vasodilation. Alternatively,
the increased exercise time without an increase in degree of
ischemia may be due to an improvement in coronary blood
flow. Although not supported by our data, others have shown
that arginine administration enhances agonist-mediated in-
creases in coronary artery blood flow (9,25).
Effect on quality of life. There was also a beneficial effect
of this nutritional-supplement approach on several aspects
of quality of life. At enrollment, patients demonstrated
average SF-36 and Seattle Angina Questionnaire scores
typical of a population of patients with class II to III angina
(23). These scores improved after active therapy. Most
notable were effects on vitality (overall sense of well-being),
role-physical (ability to perform household and job-related
chores), bodily pain and treatment satisfaction. Here again,
these effects compared favorably with other recent studies of
anti-anginal therapies on quality of life. Investigators of the
Quality of Life and Angina Research Trial (QUART)
reported quality-of-life changes in their patient population
(23). This study examined the effects of titrating traditional
therapy to minimize anginal episodes. Subjects reported a
0.6, 0.75 and 5.7 point improvement in vitality, role-
physical and treatment satisfaction scores, respectively, after
three months compared with a 6, 15.3 and 7.3 point
improvement in this study. Likewise, MacDonald et al. (39)
reported the quality-of-life changes three months after
coronary artery bypass surgery (39). They found a 14.8%,
25.4% and 1.6% improvement in vitality, role-physical and
treatment satisfaction scores, respectively. Therefore, the
effect on quality of life with this approach compares favor-
ably to the strategies of maximizing medical therapy and
bypass surgery.
Similar to other studies of this arginine-rich medical
food, there were no significant adverse events reported. The
most common minor side effects during the active period
were gastrointestinal complaints in four of the 36 subjects,
and the frequency of these was similar to those in the
placebo period. There was no effect on fasting glucose of the
study population at the end of active treatment. Of the five
patients with diabetes in the study, one reported an increase
in random blood glucose measures. There were no untoward
effects on cholesterol and triglyceride levels.
In summary, this study demonstrates that nutritional
therapy with an L-arginine-enriched medical food is safe
and improves vascular function associated with a significant
increase in exercise capacity and several aspects of quality of
life in patients with stable angina. While there was no
evidence of improvement in ECG manifestations of isch-
emia or angina onset time, there was also no worsening of
these parameters or increase in measures of cardiac work
despite the observed improvement in exercise capacity.
Reprint requests and correspondence: Dr. Andrew J. Maxwell,
Cooke Pharma, 6167 Jarvis Avenue #244, Newark, California
94560. E-mail: amaxwell@ntgr8.com.
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